Diagnosis of Pulmonary Arterial Hypertension in a Patient With Systemic Sclerosis

Jörg HW Distler, MD; Marius M Hoeper, MD; Oliver Distler, MD

Disclosures

Nat Clin Pract Rheumatol. 2008;4(3):160-164. 

In This Article

Conclusion

PAH contributes significantly to the morbidity and mortality of patients with SSc. PAH can occur in all disease stages and subsets of SSc, but patients with limited cutaneous SSc or anticentromere antibodies, those of older age, and those with decreasing DLCO (together with normal lung volumes), are at particular risk. Regular screening tests for PAH are warranted in patients with SSc, since clinical symptoms, including dyspnea on exertion, are unspecific and occur late in the course of PAH, and effective therapies are available. The most widely used screening tool is the non-invasive TTE; however, TTE can give false-negative and false-positive results, particularly in patients with borderline RVSP values on echocardiography. Lung function tests including DLCO should, therefore, be used in addition to TTE. In patients with suspected PAH, the diagnosis should be confirmed by right heart catheterization.


CLICK HERE for subscription information about this journal.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....